Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.
Interventions
DRUGSemaglutide
Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female participants aged greater than or equal to (≥) 18 years on index date * Participants with diagnosis of T2DM prior to or on index date * Participants with initiation of semaglutide OW for the first time within the identification period
Exclusion criteria
* Participants with diagnosis of type 1 diabetes prior to or on index date * Participants who were pregnant within 36 months prior to or on index date * Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Haemoglobin A1c (HbA1c) level | From baseline (3 months prior to or on the index date) to 6 months | Measured in Percentage (%). |
| Change in HbA1c level | From baseline (3 months prior to or on the index date) to 6 months | Measured in millimoles per mol (mmol/mol) |
| Proportion of participants achieving HbA1c less than (<) 7.0% | At 6 months | Measured in percentage of participants. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of participants with different demographic characteristics | At baseline (12 months prior to or on the index date) | — |
| Description of participants with different clinical characteristics | At baseline (36 months prior to or on the index date) | — |
| Change in HbA1c level | From baseline (3 months prior to or on the index date) to 12 months | Measured in %. |
| Proportion of participants with different non-antidiabetic medications | At baseline (3 months prior to or on the index date) | Measured in percentage of participants. |
| Proportion of participants with different antidiabetic medications | At baseline (3 months prior to or on the index date) | Measured in percentage of participants. |
| Proportion of participants achieving HbA1c <7.0% | At 12 months | Measured in percentage of participants. |
| Change in body weight | From baseline (3 months prior to or on the index date) to 12 months | Measured in kilograms. |
Countries
China
Outcome results
None listed